Loading clinical trials...
Loading clinical trials...
EFFICACY and SAFETY of GZR18 INJECTED EVERY 2 WEEKS (Q2W) in PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY or ARE OVERWEIGHT: a RANDOMIZED, TIRZEPATIDE- and PLACEBO-CONTROLLED STUDY
Conditions
Interventions
GZR18
Tirzepatide
Locations
20
United States
KUR Research - Trinity @ Bessemer, AL Site Network
Bessemer, Alabama, United States
KUR Research - Trinity @ Centreville Site Network
Centreville, Alabama, United States
ERG - Woodland Int'l Research Group
Little Rock, Arkansas, United States
ERG - Woodland Research Northwest
Rogers, Arkansas, United States
Ark Clinical Research Ark-Fountain Valley
Fountain Valley, California, United States
Ark Clinical Research Ark-Long Beach
Long Beach, California, United States
Start Date
February 12, 2025
Primary Completion Date
February 9, 2026
Completion Date
June 22, 2026
Last Updated
February 4, 2025
NCT07311850
NCT07049861
NCT06623669
NCT06976307
NCT06636773
NCT06878989
Lead Sponsor
Gan and Lee Pharmaceuticals, USA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions